34.74

2.20% -0.78

Cogent Biosciences Inc (COGT)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$35.52

Aprire:

$35.64

Volume 24 ore:

2.51M

Relative Volume:

0.80

Capitalizzazione di mercato:

$5.33B

Reddito:

Utile/perdita netta:

$-284.08M

Rapporto P/E:

-14.34

EPS:

-2.4234

Flusso di cassa netto:

$-234.65M

1 W Prestazione:

-10.65%

1M Prestazione:

-10.88%

6M Prestazione:

+368.83%

1 anno Prestazione:

+345.38%

Intervallo 1D:

$34.08

$35.89

Intervallo di 1 settimana:

$34.08

$38.82

Portata 52W:

$3.72

$43.73

Cogent Biosciences Inc Stock (COGT) Company Profile

Nome

Cogent Biosciences Inc

Settore

Healthcare (1131)

Industria

Biotechnology (631)

Telefono

617-945-5576

Indirizzo

275 WYMAN STREET, WALTHAM

Dipendente

205

Cinguettio

Prossima data di guadagno

2024-10-31

Ultimi documenti SEC

COGT's Discussions on Twitter

Confronta COGT con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
COGT Cogent Biosciences Inc	34.74	5.45B	0	-284.08M	-234.65M	-2.4234
VRTX Vertex Pharmaceuticals Inc	452.13	115.03B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	776.31	81.12B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	400.17	52.54B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	839.99	51.78B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	177.12	37.12B	447.02M	-1.18B	-906.14M	-6.1812

Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-11-10	Aggiornamento	Stifel	Hold → Buy
2025-11-10	Aggiornamento	Wedbush	Neutral → Outperform
2025-10-16	Iniziato	Stifel	Hold
2025-09-03	Iniziato	Raymond James	Strong Buy
2025-03-07	Iniziato	Scotiabank	Sector Outperform
2024-12-11	Downgrade	Needham	Buy → Hold
2024-02-26	Downgrade	Robert W. Baird	Outperform → Neutral
2024-02-08	Iniziato	Citigroup	Buy
2023-12-11	Downgrade	Wedbush	Outperform → Neutral
2023-12-08	Iniziato	JP Morgan	Overweight
2023-04-28	Iniziato	Robert W. Baird	Outperform
2023-03-27	Ripresa	H.C. Wainwright	Buy
2022-12-14	Iniziato	Needham	Buy
2022-06-28	Iniziato	Guggenheim	Buy
2021-10-11	Iniziato	H.C. Wainwright	Buy
2021-06-09	Ripresa	Jefferies	Buy
2020-12-23	Iniziato	Piper Sandler	Overweight
2020-10-14	Iniziato	Ladenburg Thalmann	Buy

Mostra tutto

Cogent Biosciences Inc Borsa (COGT) Ultime notizie

Jan 02, 2026

EV Market: Will Cogent Biosciences Inc stock see PE expansionJuly 2025 News Drivers & Capital Efficiency Focused Ideas - moha.gov.vn

Jan 02, 2026

Cogent Biosciences Stock Soared in 2025. Four Executives Sold Shares on the Same Day. - Barron's

Jan 02, 2026

Cogent Biosciences Stock Jumps in 2025 as Executives Sell Shares - Barron's

Jan 02, 2026

When Will Cogent Biosciences, Inc. (NASDAQ:COGT) Become Profitable? - 富途牛牛

Jan 02, 2026

Cogent Biosciences Chief Scientific Officer John Robinson Sells 50% Of Holding - simplywall.st

Jan 02, 2026

Jan 01, 2026

Voya Investment Management LLC Increases Stock Position in Cogent Biosciences, Inc. $COGT - MarketBeat

Jan 01, 2026

Dec 31, 2025

Best Biotech Stocks To Follow TodayDecember 31st - MarketBeat

Dec 31, 2025

Cogent Biosciences (COGT) stock slips as insider sales follow bezuclastinib FDA filing - ts2.tech

Dec 31, 2025

Cogent Biosciences (NASDAQ:COGT) Shares Gap Down Following Insider Selling - MarketBeat

Dec 31, 2025

Cogent Biosciences Stock Pre-Market (-4.4%): Insider Selling Overwhelms Positive NDA News - Trefis

Dec 31, 2025

Cogent Biosciences stock falls after multiple insider sales By Investing.com - Investing.com UK

Dec 30, 2025

Cogent Biosciences stock falls after multiple insider sales - Investing.com

Dec 30, 2025

Cogent Biosciences (NASDAQ:COGT) Insider Sells $3,198,245.40 in Stock - MarketBeat

Dec 30, 2025

Cogent Biosciences (NASDAQ:COGT) Insider John Edward Robinson Sells 90,000 Shares - MarketBeat

Dec 30, 2025

Insider Sell: Jessica Sachs Sells 82,642 Shares of Cogent Biosci - GuruFocus

Dec 30, 2025

Cogent Biosciences Insider Sold Shares Worth $3,486,600, According to a Recent SEC Filing - marketscreener.com

Dec 30, 2025

Cogent Biosciences Insider Sold Shares Worth $3,198,245, According to a Recent SEC Filing - marketscreener.com

Dec 30, 2025

Cogent Biosciences Insider Sold Shares Worth $2,978,360, According to a Recent SEC Filing - marketscreener.com

Dec 30, 2025

Cogent Biosciences Insider Sold Shares Worth $2,515,500, According to a Recent SEC Filing - marketscreener.com

Dec 30, 2025

Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis - The Globe and Mail

Dec 30, 2025

Why Cogent Biosciences stock is down today after its FDA filing for bezuclastinib - ts2.tech

Dec 30, 2025

Cogent Biosciences Submits New Drug Application for Bezuclastinib for Non-Advanced Systemic Mastocytosis - marketscreener.com

Dec 30, 2025

Cogent Biosciences (COGT) Advances Bezuclastinib with FDA Submis - GuruFocus

Dec 30, 2025

Cogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Dec 30, 2025

Dec 28, 2025

JPMorgan Raises Cogent Biosciences (COGT) PT to $67 on Sector Model Update - Insider Monkey

Dec 28, 2025

Dec 27, 2025

Cogent Biosciences jumps after strong late-stage results in advanced systemic mastocytosis - MSN

Dec 27, 2025

Dec 26, 2025

Certain Stock Options of Cogent Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 27-DEC-2025. - marketscreener.com

Dec 26, 2025